UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2025

Balchem Corporation
(Exact name of registrant as specified in its charter)

Maryland
 
1-13648
 
13-2578432
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)

5 Paragon Drive, Montvale, NJ 07645
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (845) 326-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $.06-2/3 per share
 BCPC
 The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company        ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐

Item 7.01
Regulation FD Disclosure.

On December 10, 2025, Balchem Corporation (the “Company”) issued a press release announcing a dividend declared by the Company's Board of Directors on December 9, 2025.  A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
 
Further, on December 9, 2025, the Board of Directors of the Company approved a new stock repurchase program which replaces the previous program that was in place and authorizes the repurchase of up to, and including, 4 million shares of the Company's ordinary shares.  This new stock repurchase program has no expiration date, does not oblige the Company to acquire any particular amount of the Company’s ordinary shares, and may be terminated at any time.

Share repurchases may be made from time to time in the open market, including pursuant to a share repurchase agreement in compliance with Rule 10b-18 or a trading plan established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions at the discretion of management. 

Item 9.01
Financial Statements and Exhibits.

(d)  Exhibits

Exhibit Number
Description
104
Press Release dated December 10, 2025
Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BALCHEM CORPORATION
 
(Registrant)
 
 
 
By:
 /s/ Hatsuki Miyata
 
 
Hatsuki Miyata
 
Executive Vice President, Chief Legal Officer and Secretary
 
 
Date: December 10, 2025